PRNewswire: August 17, 2016 – BOSTON, MA, U.S.A. – Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (“Juniper” or the “company”), a women’s health therapeutics company, today announced that a recently completed phase 2b clinical trial evaluating its 10% lidocaine bioadhesive vaginal gel, COL-1077, for…
